Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Hepatocellular carcinoma displays distinct DNA methylation signatures with potential as clinical predictors.

Hernandez-Vargas H, Lambert MP, Le Calvez-Kelm F, Gouysse G, McKay-Chopin S, Tavtigian SV, Scoazec JY, Herceg Z.

PLoS One. 2010 Mar 17;5(3):e9749. doi: 10.1371/journal.pone.0009749.

2.

[Aberrant methylation of multiple genes and its clinical implication in hepatocellular carcinoma].

Lou C, Yang B, Gao YT, Wang YJ, Nie FH, Yuan Q, Zhang CL, Du Z.

Zhonghua Zhong Liu Za Zhi. 2008 Nov;30(11):831-6. Chinese.

PMID:
19173828
3.

Methylation profiling of twenty promoter-CpG islands of genes which may contribute to hepatocellular carcinogenesis.

Yu J, Ni M, Xu J, Zhang H, Gao B, Gu J, Chen J, Zhang L, Wu M, Zhen S, Zhu J.

BMC Cancer. 2002 Nov 15;2:29. Epub 2002 Nov 15.

4.

Aberrant DNA methylation distinguishes hepatocellular carcinoma associated with HBV and HCV infection and alcohol intake.

Lambert MP, Paliwal A, Vaissière T, Chemin I, Zoulim F, Tommasino M, Hainaut P, Sylla B, Scoazec JY, Tost J, Herceg Z.

J Hepatol. 2011 Apr;54(4):705-15. doi: 10.1016/j.jhep.2010.07.027. Epub 2010 Sep 25.

PMID:
21146512
5.

Methylation of Tip30 promoter is associated with poor prognosis in human hepatocellular carcinoma.

Lu B, Ma Y, Wu G, Tong X, Guo H, Liang A, Cong W, Liu C, Wang H, Wu M, Zhao J, Guo Y.

Clin Cancer Res. 2008 Nov 15;14(22):7405-12. doi: 10.1158/1078-0432.CCR-08-0409.

6.

[Correlation between epigenetic alterations in the insulin growth factor-II gene and hepatocellular carcinoma].

Dong ZZ, Yao DF, Wu W, Qiu LW, Yao NH, Yan XD, Yu DD, Chen J.

Zhonghua Gan Zang Bing Za Zhi. 2012 Aug;20(8):593-7. doi: 10.3760/cma.j.issn.1007-3418.2012.08.011. Chinese.

PMID:
23207153
7.

DNA methylation-based prognosis and epidrivers in hepatocellular carcinoma.

Villanueva A, Portela A, Sayols S, Battiston C, Hoshida Y, Méndez-González J, Imbeaud S, Letouzé E, Hernandez-Gea V, Cornella H, Pinyol R, Solé M, Fuster J, Zucman-Rossi J, Mazzaferro V, Esteller M, Llovet JM; HEPTROMIC Consortium.

Hepatology. 2015 Jun;61(6):1945-56. doi: 10.1002/hep.27732. Epub 2015 Mar 18.

8.

High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adduct levels in human hepatocellular carcinoma.

Zhang YJ, Ahsan H, Chen Y, Lunn RM, Wang LY, Chen SY, Lee PH, Chen CJ, Santella RM.

Mol Carcinog. 2002 Oct;35(2):85-92.

PMID:
12325038
9.

Functional switching of TGF-beta1 signaling in liver cancer via epigenetic modulation of a single CpG site in TTP promoter.

Sohn BH, Park IY, Lee JJ, Yang SJ, Jang YJ, Park KC, Kim DJ, Lee DC, Sohn HA, Kim TW, Yoo HS, Choi JY, Bae YS, Yeom YI.

Gastroenterology. 2010 May;138(5):1898-908. doi: 10.1053/j.gastro.2009.12.044. Epub 2009 Dec 29.

PMID:
20038433
10.

Epigenetic mechanisms in hepatocellular carcinoma: how environmental factors influence the epigenome.

Herceg Z, Paliwal A.

Mutat Res. 2011 May-Jun;727(3):55-61. doi: 10.1016/j.mrrev.2011.04.001. Epub 2011 Apr 15. Review.

PMID:
21514401
11.

Epigenetic methylation and expression of caspase 8 and survivin in hepatocellular carcinoma.

Cho S, Lee JH, Cho SB, Yoon KW, Park SY, Lee WS, Park CH, Joo YE, Kim HS, Choi SK, Rew JS.

Pathol Int. 2010 Mar;60(3):203-11. doi: 10.1111/j.1440-1827.2009.02507.x.

PMID:
20403046
12.

Hypomethylated P4 promoter induces expression of the insulin-like growth factor-II gene in hepatocellular carcinoma in a Chinese population.

Tang SH, Yang DH, Huang W, Zhou HK, Lu XH, Ye G.

Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4171-7.

13.

Aberrant DNA methylation profile and frequent methylation of KLK10 and OXGR1 genes in hepatocellular carcinoma.

Lu CY, Hsieh SY, Lu YJ, Wu CS, Chen LC, Lo SJ, Wu CT, Chou MY, Huang TH, Chang YS.

Genes Chromosomes Cancer. 2009 Dec;48(12):1057-68. doi: 10.1002/gcc.20708.

PMID:
19760608
14.

Identification of genes preferentially methylated in hepatitis C virus-related hepatocellular carcinoma.

Deng YB, Nagae G, Midorikawa Y, Yagi K, Tsutsumi S, Yamamoto S, Hasegawa K, Kokudo N, Aburatani H, Kaneda A.

Cancer Sci. 2010 Jun;101(6):1501-10. doi: 10.1111/j.1349-7006.2010.01549.x. Epub 2010 Feb 27.

15.

DNA binding protein A expression and methylation status in hepatocellular carcinoma and the adjacent tissue.

Yasen M, Obulhasim G, Kajino K, Mogushi K, Mizushima H, Tanaka S, Tanaka H, Hino O, Arii S.

Int J Oncol. 2012 Mar;40(3):789-97. doi: 10.3892/ijo.2011.1282. Epub 2011 Dec 6.

PMID:
22159460
16.

Variable DNA methylation patterns associated with progression of disease in hepatocellular carcinomas.

Gao W, Kondo Y, Shen L, Shimizu Y, Sano T, Yamao K, Natsume A, Goto Y, Ito M, Murakami H, Osada H, Zhang J, Issa JP, Sekido Y.

Carcinogenesis. 2008 Oct;29(10):1901-10. doi: 10.1093/carcin/bgn170. Epub 2008 Jul 16.

PMID:
18632756
17.

Elucidating the landscape of aberrant DNA methylation in hepatocellular carcinoma.

Song MA, Tiirikainen M, Kwee S, Okimoto G, Yu H, Wong LL.

PLoS One. 2013;8(2):e55761. doi: 10.1371/journal.pone.0055761. Epub 2013 Feb 20.

18.

Comparison of genome-scale DNA methylation profiles in hepatocellular carcinoma by viral status.

Song MA, Kwee SA, Tiirikainen M, Hernandez BY, Okimoto G, Tsai NC, Wong LL, Yu H.

Epigenetics. 2016 Jun 2;11(6):464-74. doi: 10.1080/15592294.2016.1151586. Epub 2016 Jun 1.

19.

The assessment of methylated BASP1 and SRD5A2 levels in the detection of early hepatocellular carcinoma.

Tsunedomi R, Ogawa Y, Iizuka N, Sakamoto K, Tamesa T, Moribe T, Oka M.

Int J Oncol. 2010 Jan;36(1):205-12.

PMID:
19956849
20.

CpG island methylator phenotype associated with tumor recurrence in tumor-node-metastasis stage I hepatocellular carcinoma.

Li B, Liu W, Wang L, Li M, Wang J, Huang L, Huang P, Yuan Y.

Ann Surg Oncol. 2010 Jul;17(7):1917-26. doi: 10.1245/s10434-010-0921-7. Epub 2010 Jan 29.

PMID:
20112070

Supplemental Content

Support Center